Comparison of liposomal bupivacaine versus bupivacaine with epinephrine versus the
combination in postoperative pain management following spinal surgery
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METHODS

BACKGROUND
• Liposomal bupivacaine is a long-acting, sustained-release
formulation of bupivacaine HCl.1
• Liposomal bupivacaine is formulated using a DepoFoam®
lipid-based delivery system, which encapsulates the drug
in multivesicular liposomal particles, and releases the drug
over a desired period of time without altering the drug
molecule.1

• Retrospective medical record review
• Data for patients who were administered liposomal
bupivacaine, bupivacaine with epinephrine, or both liposomal
bupivacaine and bupivacaine with epinephrine from January
2016 to September 2021 at Valley Hospital Medical Center
will be assessed
Inclusion Criteria

• Liposomal bupivacaine was studied vs. placebo in
interscalene brachial plexus nerve block and showed
benefit in reducing pain intensity.2

• In a study that compared liposomal bupivacaine vs. saline
following posterior lumbar decompression and fusion
(PLDF) surgery, liposomal bupivacaine did not significantly
alter the 72-hour postoperative opioid requirement (11.6
MME vs. 13.4 MME, P = 0.4), and pain scales and length
of stay were not significantly different.3
• Currently, there are no head-to-head comparisons of
liposomal bupivacaine vs. bupivacaine HCl in spinal
surgery.5

STUDY OBJECTIVES
• The primary objective of this study is to compare the 72hour postoperative opioid consumption after administration
of liposomal bupivacaine versus bupivacaine with
epinephrine versus both liposomal bupivacaine and
bupivacaine with epinephrine.
• The secondary objective of this study is to assess the
reduction in pain scores, length of stay, and non-opioid
pain medication consumption.

Exclusion Criteria
Data to be collected
• Discharged on the same date as spinal surgery
• No documented administration times for bupivacaine
therapy

• The following data will be collected:
•
•
•
•
•
•
•
•
•

Age
Gender
Ethnicity
Weight
Height
Type of surgery
Date of surgery
Date of hospital discharge
Dose of liposomal
bupivacaine
• Dose of bupivacaine with
epinephrine
• Time of administration
• Pain medications
administered pre-surgery

• Total opioid consumption within 72 hours post-surgery will
be reported as morphine milligram equivalents.
• Opioid consumption will be evaluated at 24 hours, 24 to 48
hours and 48 to 72 hours post-surgery using the KruskalWallis test. Pain scores and length of stay will be evaluated
using the Kruskal-Wallis test. The use of non-opioid pain
medications will be evaluated using the Fisher’s exact test.
• Adverse events will be analyzed using Fisher’s exact test.

• 18 years or older
• Spinal surgery
• Admitted to the hospital for > 24 hours

• However, limited evidence suggests that liposomal
bupivacaine may safely decrease postoperative opioid
requirements, pain scores, and length of stay in patients
undergoing spine surgery.3, 4, 5

DATA ANALYSIS

• Pain medications
administered within 72
hours post-surgery
• Muscle relaxant
medications administered
within 72 hours postsurgery
• Postoperative numerical
pain scores
• Adverse events
• Pain medications prior to
admission
• Opioids prescribed at
discharge
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